RS58289B1 - Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije - Google Patents
Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemijeInfo
- Publication number
- RS58289B1 RS58289B1 RS20190039A RSP20190039A RS58289B1 RS 58289 B1 RS58289 B1 RS 58289B1 RS 20190039 A RS20190039 A RS 20190039A RS P20190039 A RSP20190039 A RS P20190039A RS 58289 B1 RS58289 B1 RS 58289B1
- Authority
- RS
- Serbia
- Prior art keywords
- leukemia virus
- feline leukemia
- vaccine containing
- envelope gene
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509912P | 2011-07-20 | 2011-07-20 | |
| PCT/US2012/023658 WO2013012446A1 (en) | 2011-07-20 | 2012-02-02 | Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| EP12705199.3A EP2734230B1 (en) | 2011-07-20 | 2012-02-02 | Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58289B1 true RS58289B1 (sr) | 2019-03-29 |
Family
ID=45722710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190039A RS58289B1 (sr) | 2011-07-20 | 2012-02-02 | Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8895027B2 (sr) |
| EP (1) | EP2734230B1 (sr) |
| JP (2) | JP6084970B2 (sr) |
| CN (1) | CN103957932B (sr) |
| AU (2) | AU2012284558B2 (sr) |
| BR (1) | BR112014001287B1 (sr) |
| CA (1) | CA2842055C (sr) |
| CY (1) | CY1125328T1 (sr) |
| DK (1) | DK2734230T3 (sr) |
| ES (1) | ES2720150T3 (sr) |
| HR (1) | HRP20190271T1 (sr) |
| HU (1) | HUE043547T2 (sr) |
| IL (1) | IL230460B (sr) |
| IN (1) | IN2014CN00547A (sr) |
| LT (1) | LT2734230T (sr) |
| MX (1) | MX351642B (sr) |
| PL (1) | PL2734230T3 (sr) |
| PT (1) | PT2734230T (sr) |
| RS (1) | RS58289B1 (sr) |
| RU (1) | RU2591817C2 (sr) |
| SI (1) | SI2734230T1 (sr) |
| TR (1) | TR201901466T4 (sr) |
| WO (1) | WO2013012446A1 (sr) |
| ZA (1) | ZA201400349B (sr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017005687A (es) | 2014-11-03 | 2017-08-21 | Merial Inc | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. |
| EP3691679A2 (en) * | 2017-10-06 | 2020-08-12 | Virbac | Feline vaccines conferring early protection |
| CN111848785B (zh) * | 2020-07-10 | 2022-09-06 | 青岛博隆基因工程有限公司 | 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
| DK175363B1 (da) | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
| IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
| CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| EP0699758B1 (en) * | 1988-12-13 | 2002-07-24 | President And Fellows Of Harvard College | Prototype felv isolates for use in disease models and vaccines |
| US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2712603B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| US5529780A (en) | 1994-03-30 | 1996-06-25 | Virogenetics Corporation | Nucleotide and amino acid sequences of canine herpesvirus gB and gC |
| EP0826063A1 (en) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
| EP0803573A1 (en) | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ） |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
| US6017537A (en) | 1998-12-18 | 2000-01-25 | Connaught Laboratories, Inc. | Formyl methionyl peptide vaccine adjuvant |
| US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
| FR2796397B1 (fr) | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
| MXPA02003108A (es) | 1999-09-25 | 2003-10-14 | Univ Iowa Res Found | Acidos nucleicos inmunoestimuladores. |
| US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| EP1203819A3 (en) | 2000-10-06 | 2002-08-07 | Transgene S.A. | Anti-inflammatory vectors |
| CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
| FR2829498B1 (fr) | 2001-09-11 | 2003-11-28 | Merial Sas | Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins |
| US7078507B2 (en) | 2001-11-09 | 2006-07-18 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Synthetic genes for malarial proteins and methods of use |
| WO2004024027A2 (en) | 2002-06-07 | 2004-03-25 | University Of Florida | Endodontic files made using bulk metallic glasses |
| JP4411213B2 (ja) * | 2002-09-23 | 2010-02-10 | モロゲン・アーゲー | ネコ白血病ウィルスによるネコ感染症のようなオンコウィルス感染症に対するワクチン |
| DE602005022056D1 (de) * | 2004-03-30 | 2010-08-12 | Centre Nat Rech Scient | Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind |
| DK1765387T3 (da) | 2004-06-04 | 2013-03-04 | Merial Ltd | NÅLE-FRI ADMINISTRATION AF FeLV-VACCINER |
| US7998733B2 (en) * | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| PL1954308T3 (pl) * | 2005-09-16 | 2012-01-31 | Merial Ltd | Stabilizatory do liofilizowanych szczepionek |
| CN101849013A (zh) * | 2007-05-30 | 2010-09-29 | 惠氏有限责任公司 | 猫抗原的浣熊痘病毒表达基因 |
-
2012
- 2012-02-02 TR TR2019/01466T patent/TR201901466T4/tr unknown
- 2012-02-02 RU RU2014106295/15A patent/RU2591817C2/ru active
- 2012-02-02 EP EP12705199.3A patent/EP2734230B1/en active Active
- 2012-02-02 WO PCT/US2012/023658 patent/WO2013012446A1/en active Application Filing
- 2012-02-02 RS RS20190039A patent/RS58289B1/sr unknown
- 2012-02-02 HU HUE12705199A patent/HUE043547T2/hu unknown
- 2012-02-02 US US13/364,993 patent/US8895027B2/en active Active
- 2012-02-02 CA CA2842055A patent/CA2842055C/en active Active
- 2012-02-02 JP JP2014521612A patent/JP6084970B2/ja active Active
- 2012-02-02 PT PT12705199T patent/PT2734230T/pt unknown
- 2012-02-02 CN CN201280041551.1A patent/CN103957932B/zh active Active
- 2012-02-02 LT LTEP12705199.3T patent/LT2734230T/lt unknown
- 2012-02-02 SI SI201231522T patent/SI2734230T1/sl unknown
- 2012-02-02 BR BR112014001287-3A patent/BR112014001287B1/pt active IP Right Grant
- 2012-02-02 MX MX2014000625A patent/MX351642B/es active IP Right Grant
- 2012-02-02 AU AU2012284558A patent/AU2012284558B2/en active Active
- 2012-02-02 DK DK12705199.3T patent/DK2734230T3/en active
- 2012-02-02 IN IN547CHN2014 patent/IN2014CN00547A/en unknown
- 2012-02-02 ES ES12705199T patent/ES2720150T3/es active Active
- 2012-02-02 PL PL12705199T patent/PL2734230T3/pl unknown
-
2014
- 2014-01-14 IL IL230460A patent/IL230460B/en active IP Right Grant
- 2014-01-16 ZA ZA2014/00349A patent/ZA201400349B/en unknown
- 2014-10-06 US US14/507,455 patent/US9856295B2/en active Active
-
2016
- 2016-10-31 JP JP2016212839A patent/JP6240294B2/ja active Active
-
2017
- 2017-06-26 AU AU2017204298A patent/AU2017204298A1/en not_active Abandoned
-
2019
- 2019-02-11 HR HRP20190271TT patent/HRP20190271T1/hr unknown
- 2019-02-14 CY CY20191100209T patent/CY1125328T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202434A1 (en) | Virus vectors for highly efficient transgene delivery | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| SG10201801947YA (en) | Recombinant subunit dengue virus vaccine | |
| EP2678005A4 (en) | GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS | |
| EP2542703A4 (en) | NEW HIV-1 ENVELOPE GLYCOPROTEIN | |
| IL231043A (en) | vaccine | |
| IL231132A0 (en) | Viral cleaning methods | |
| HK1245104A1 (zh) | Dna疫苗 | |
| ZA201309516B (en) | Protein matrix vaccine compositions including polycations | |
| ZA201209260B (en) | Novel intergenic elements for enhancing gene expression | |
| HRP20190271T1 (hr) | Rekombinantno cjepivo protiv virusa mačje leukemije koje sadrži optimirajući gen proteina omotača virusa mačje leukemije | |
| GB201119999D0 (en) | Vaccine | |
| IL239152A0 (en) | Biological mixture inactivated from viruses | |
| AP2013007180A0 (en) | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto | |
| EP2543387A4 (en) | MUCOSAL VACCINE | |
| EP2747779A4 (en) | VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION | |
| EP2763699A4 (en) | VACCINE | |
| EP2678043A4 (en) | RECOMBINANT MUMPSVIRUS VACCINE | |
| HK1202070A1 (en) | Vaccine for tumor immunotherapy | |
| GB201004143D0 (en) | Promoter sequence for DNA and viral vectors | |
| EP2615104A4 (en) | LIPOSOMAL VACCINE AGAINST HEPATITIS C VIRUS | |
| GB201218465D0 (en) | Viral infection cofactor | |
| GB201120000D0 (en) | Vaccine | |
| GB2496849B (en) | Improved DNA plasmid system | |
| AU2011901988A0 (en) | Recombinant viral vaccines |